Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have
raised concerns about resistance to neutralizing antibodies elicited by previous infection or …

Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we
evaluate 254 COVID-19 patients longitudinally up to 8 months and find durable broad-based …

The barrier to curing HIV-1 is thought to reside primarily in CD4 + T cells containing silent
proviruses. To characterize these latently infected cells, we studied the integration profile of HIV…

3BNC117 is a broad and potent neutralizing antibody to HIV-1 that targets the CD4 binding
site on the viral envelope spike. When administered passively, this antibody can prevent …

Long COVID or post-acute sequelae of SARS-CoV-2 (PASC) is a clinical syndrome featuring
diverse symptoms that can persist for months following acute SARS-CoV-2 infection. The …

Conventional memory CD8+ T cells and mucosal-associated invariant T cells (MAIT cells)
are found in blood, liver, and mucosal tissues and have similar effector potential following …

Broadly neutralizing antibodies (bNAbs) against HIV-1 envelope (Env) inform vaccine design
and are potential therapeutic agents. We identified SF12 and related bNAbs with up to 62…

SARS-CoV-2 has infected over 160 million and caused more than 3 million deaths to date.
Most individuals (>80%) have mild symptoms and recover in the outpatient setting, but …

The emergence of SARS-CoV-2 variants raises concerns about their resistance to neutralizing
antibodies elicited from previous infection, or from vaccination. Here we examined …

Background VRC01, a potent, broadly neutralizing monoclonal antibody, inhibits simian-HIV
infection in animal models. The HVTN 104 study assessed the safety and pharmacokinetics …